Mirum Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Mirum Pharmaceuticals, Inc. (MIRM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-87.94-163.42-135.67-83.99103.27-52.55
Depreciation & Amortization24.9811.953.680.600.550.00
Deferred Income Tax0.000.00-6.580.000.000.00
Stock Based Compensation48.4435.0227.0123.0912.550.00
Change in Working Capital22.59-49.06-21.0516.98-0.87-2.85
Change in Accounts Receivable-11.43-43.97-20.730.000.000.00
Change in Inventory-3.17-0.97-3.45-0.500.000.00
Change in Accounts Payable40.3130.787.6422.663.680.00
Change in Other Working Capital-3.13-5.05-4.51-5.18-3.070.00
Other Operating Activities0.5978.745.8918.7016.0916.04
Net Cash from Operating Activities10.33-70.94-120.14-132.76-89.08-39.36
Investing Activities
Capital Expenditures-0.9920.11-0.28-0.020.230.28
Acquisitions0.00-212.760.000.000.000.00
Purchases of Investments-69.13125.677.98-40.4338.100.00
Sales/Maturities of Investments-20.00125.677.98-19.0038.10-127.50
Other Investing Activities-20.000.000.00108.0026.760.00
Net Cash from Investing Activities-90.13-107.207.7048.5537.87-127.78
Financing Activities
Common Stock Issued17.70216.68114.649.01131.0967.20
Other Financing Activities0.00-195.86-5.5564.4549.420.00
Net Cash from Financing Activities17.70336.60109.0973.47181.29127.18
Summary
Effect of Forex Changes on Cash-1.30-0.130.010.000.03-0.03
Net Change in Cash-63.40158.32-3.34-10.75130.12-39.97
Cash at Beginning of Period286.33128.00131.34142.0911.9751.96
Cash at End of Period222.93158.49128.00131.34142.0911.97
Free Cash Flow9.33-91.05-120.41-132.78-89.30-39.64
Supplemental Disclosures
Interest Paid12.656.820.000.000.000.00
Income Taxes Paid1.000.130.000.000.010.02